BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 2409821)

  • 1. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
    Brace LD; Venton DL; Le Breton GC
    Am J Physiol; 1985 Jul; 249(1 Pt 2):H8-13. PubMed ID: 2409821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
    Brace LD; Venton DL; Le Breton GC
    Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
    Parise LV; Venton DL; Le Breton GC
    J Pharmacol Exp Ther; 1982 Jul; 222(1):276-81. PubMed ID: 7086705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
    Parise LV; Venton DL; Le Breton GC
    J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
    Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK
    J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostaglandin H2 directly lowers human platelet cAMP levels.
    Rybicki JP; Le Breton GC
    Thromb Res; 1983 Jun; 30(5):407-14. PubMed ID: 6310815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor.
    Le Breton GC; Venton DL; Enke SE; Halushka PV
    Proc Natl Acad Sci U S A; 1979 Aug; 76(8):4097-101. PubMed ID: 291066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The thromboxane antagonist, 13-azaprostanoic acid, inhibits arachidonic acid-induced Ca2+ release from isolated platelet membrane vesicles.
    Rybicki JP; Venton DL; Le Breton GC
    Biochim Biophys Acta; 1983 Mar; 751(1):66-73. PubMed ID: 6830832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboxane-induced phosphatidate formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium.
    Pollock WK; Armstrong RA; Brydon LJ; Jones RL; MacIntyre DE
    Biochem J; 1984 May; 219(3):833-42. PubMed ID: 6234886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists.
    Hanasaki K; Arita H
    Biochem Pharmacol; 1988 Oct; 37(20):3923-9. PubMed ID: 2973322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of thromboxane receptors in human platelets.
    Jones RL; Wilson NH; Armstrong RA
    Adv Exp Med Biol; 1985; 192():67-81. PubMed ID: 3010674
    [No Abstract]   [Full Text] [Related]  

  • 13. Decrease in agonist affinity for human platelet thromboxane A2/prostaglandin H2 receptors induced by a platelet-derived supernatant.
    Dorn GW; Burch RM; Kochel PJ; Mais DE; Halushka PV
    Biochem Pharmacol; 1987 Jun; 36(12):1913-7. PubMed ID: 2954555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
    Harris RH; Nichols R; Schmeling JW; Ramwell PW
    Thromb Res; 1981 Sep; 23(6):521-32. PubMed ID: 6798707
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostacyclin potentiates 13-azaprostanoic acid-induced platelet deaggregation.
    Parise LV; Venton DL; Le Breton GC
    Thromb Res; 1982 Dec; 28(6):721-30. PubMed ID: 6301090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-(6-carboxyhexyl)cyclopentanone hexylhydrazone: a potent inhibitor of the blood platelet cyclo-oxygenase.
    Le Breton GC; Hung SC; Ghali NI; Venton DL
    Prostaglandins; 1984 Apr; 27(4):543-51. PubMed ID: 6427851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 12-HETE inhibits the binding of PGH2/TXA2 receptor ligands in human platelets.
    Fonlupt P; Croset M; Lagarde M
    Thromb Res; 1991 Jul; 63(2):239-48. PubMed ID: 1837628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of collagen-induced platelet activation by 5'-p-fluorosulfonylbenzoyl adenosine: evidence for an adenosine diphosphate requirement and synergistic influence of prostaglandin endoperoxides.
    Colman RW; Figures WR; Scearce LM; Strimpler AM; Zhou FX; Rao AK
    Blood; 1986 Aug; 68(2):565-70. PubMed ID: 3730618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
    Patscheke H; Stegmeier K
    Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
    Hornberger WB; Patscheke H
    Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.